LENZ Therapeutics to Report Second Quarter 2024 Financial Results on August 14, 2024
LENZ Therapeutics (Nasdaq: LENZ), a late clinical-stage biopharmaceutical company, has announced it will report its second quarter 2024 financial results on August 14, 2024. The company, which is developing the first aceclidine-based eye drop for presbyopia, will host a webcast at 4:30 p.m. ET to present the results and provide a business update. Investors and interested parties can access the live webcast through the company's website, where a replay will be available for 30 days following the event.
LENZ Therapeutics (Nasdaq: LENZ), una azienda biofarmaceutica in fase clinica avanzata, ha annunciato che riporterà i suoi risultati finanziari del secondo trimestre 2024 il 14 agosto 2024. L'azienda, che sta sviluppando il primo collirio a base di aceclidina per la presbiopia, ospiterà un webcast alle 16:30 ET per presentare i risultati e fornire un aggiornamento aziendale. Gli investitori e le parti interessate possono accedere al webcast dal vivo tramite il sito web dell'azienda, dove sarà disponibile una registrazione per 30 giorni dopo l'evento.
LENZ Therapeutics (Nasdaq: LENZ), una compañía biofarmacéutica en etapa clínica avanzada, ha anunciado que reportará sus resultados financieros del segundo trimestre de 2024 el 14 de agosto de 2024. La compañía, que está desarrollando la primera gota ocular a base de aceclidina para la presbicia, llevará a cabo una transmisión en línea a las 4:30 p.m. ET para presentar los resultados y proporcionar una actualización de negocios. Los inversores y partes interesadas pueden acceder a la transmisión en vivo a través del sitio web de la compañía, donde una repetición estará disponible durante 30 días después del evento.
LENZ Therapeutics (Nasdaq: LENZ)는 후기 임상 단계의 바이오 제약 회사로서 2024년 8월 14일에 2024년 2분기 재무 결과를 발표할 것이라고 밝혔습니다. 이 회사는 노안 치료를 위한 최초의 아세클리딘 기반 점안액을 개발 중이며, 오후 4시 30분 ET에 결과를 발표하고 비즈니스 업데이트를 제공하는 웹캐스트를 개최합니다. 투자자와 관심 있는 당사자는 회사 웹사이트를 통해 실시간 웹캐스트에 접근할 수 있으며, 이벤트 후 30일 동안 다시 보기 서비스가 제공됩니다.
LENZ Therapeutics (Nasdaq: LENZ), une entreprise biopharmaceutique en phase clinique avancée, a annoncé qu'elle publiera ses résultats financiers pour le deuxième trimestre 2024 le 14 août 2024. L'entreprise, qui développe le premier collyre à base d'aceclidine pour la presbytie, organisera un webcast à 16h30 ET pour présenter les résultats et fournir une mise à jour commerciale. Les investisseurs et les parties intéressées peuvent accéder au webcast en direct via le site Web de l'entreprise, où un enregistrement sera disponible pendant 30 jours après l'événement.
LENZ Therapeutics (Nasdaq: LENZ), ein biopharmazeutisches Unternehmen in der späten klinischen Phase, hat angekündigt, dass es am 14. August 2024 seine Finanzergebnisse für das zweite Quartal 2024 bekannt geben wird. Das Unternehmen, das die erste aceclidinbasierte Augenlösung gegen Presbyopie entwickelt, wird um 16:30 Uhr ET ein Webcast veranstalten, um die Ergebnisse vorzustellen und ein Unternehmensupdate zu geben. Investoren und Interessierte können den Live-Webcast über die Website des Unternehmens abrufen, wo eine Wiederholung für 30 Tage nach der Veranstaltung verfügbar sein wird.
- LENZ is in the late clinical-stage of developing a novel treatment for presbyopia
- The company is publicly traded on Nasdaq, indicating a certain level of financial stability and investor interest
- None.
SAN DIEGO, Aug. 07, 2024 (GLOBE NEWSWIRE) -- LENZ Therapeutics, Inc. (Nasdaq: LENZ or “LENZ” or the “Company”), a late clinical-stage biopharmaceutical company focused on developing the first aceclidine-based eye to improve near vision in people with presbyopia, today announced it will host a webcast on Wednesday, August 14, 2024 at 4:30 p.m. ET to report its second quarter 2024 financial results and provide a business update.
The live webcast can be accessed here and on the LENZ Therapeutics website at www.LENZ-tx.com in the Investors & Media section. A replay of the webcast will be available on the Company’s website for 30 days following the event.
About LENZ Therapeutics
LENZ Therapeutics is a late clinical-stage biopharmaceutical company focused on the development and commercialization of the first aceclidine-based eye drop to improve vision in patients diagnosed with presbyopia. LENZ’s product candidate, LNZ100 is a preservative-free, single-use, once-daily eye drops containing aceclidine. LNZ100 was evaluated in the registration-enabling Phase 3 CLARITY trials as a potential therapy for the treatment of presbyopia, a condition impacting an estimated 1.8 billion people globally and 128 million people in the United States. LENZ is committed to commercializing an ideal pharmaceutical presbyopia solution that enhances vision for “all eyes, all day.” LENZ is headquartered in San Diego, California. For more information, visit: LENZ-Tx.com.
Contacts:
Dan Chevallard
LENZ Therapeutics
IR@LENZ-Tx.com
FAQ
When will LENZ Therapeutics report its Q2 2024 financial results?
What is LENZ Therapeutics developing?
How can investors access LENZ Therapeutics' Q2 2024 financial results webcast?
What is LENZ Therapeutics' stock symbol?
